Ophthalmologic findings in hepatitis C patients treated with pegylated interferon α-2b and ribavirin

被引:2
|
作者
De Novelli, Fernando Jose
Przysiezny, Andre
Rosa, Evandro Luis
Liermann Garcia, Raquel Francine
Nobrega, Mario Junqueira
机构
[1] Hepatol Clin Sao Jose Reg Hosp, Sao Jose, SC, Brazil
[2] Sadalla Amin Ghanem Eye Hosp, Vitreoretinal Dept, Joinville, SC, Brazil
关键词
Antiviral agents/adverse effects; Hepatitis C; chronic/drug therapy; Interferon-alpha/adverse effects; Retinal diseases/chemically induced; Ribavirin/adverse effects; CHRONIC ACTIVE HEPATITIS; CHRONIC VIRAL-HEPATITIS; INDUCED RETINOPATHY; RETINAL COMPLICATIONS; VIRUS-INFECTION; ALPHA THERAPY; HYPERTENSION; ALFA;
D O I
10.5935/0004-2749.20140045
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To identify the effect of pegylated interferon alpha-2b and ribavirin treatment in the ocular fundus examination, visual acuity, and visual field. Methods: Prospective observational study was performed at the Hepatology Clinic of Sao Jose Regional Hospital and at the Vitreoretinal Department at the Sadalla Amin Ghanem Eye Hospital in patients with chronic hepatitis C before and during treatment with pegylated interferon alpha-2b together with ribavirin. Results: Six (37.5%) of 16 patients developed retinopathy during the treatment, two of which (12.5%) presented retinal hemorrhage, and four patients (6 eyes) presented cotton-wool spots (25%) that regressed during the treatment. One patient (6.25%) presented transient decrease in visual acuity during the treatment and recovered spontaneously without specific therapy. Conclusion: Recommended treatment methods for hepatitis C may cause transient retinopathy, commonly without any damage to visual function in most patients. Although ocular involvement is rare, follow-up with an ophthalmologist is recommended during the course of the hepatitis C medication.
引用
收藏
页码:178 / 181
页数:4
相关论文
共 50 条
  • [31] Efficacy and Tolerability of Pegylated Interferon-α2a plus Ribavirin versus Pegylated Interferon-α2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients
    Lee, Seok
    Kim, In Hee
    Kim, Seong Hun
    Kim, Sang Wook
    Lee, Seung Ok
    Lee, Soo Teik
    Kim, Dae Ghon
    Lee, Chang Seop
    Choi, Chang Soo
    Cho, Eun Young
    Kim, Haak Cheoul
    INTERVIROLOGY, 2010, 53 (03) : 146 - 153
  • [32] Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon
    Herrmann, E
    Lee, JH
    Marinos, G
    Modi, M
    Zeuzem, S
    HEPATOLOGY, 2003, 37 (06) : 1351 - 1358
  • [33] Ophthalmologic Complications in Children With Chronic Hepatitis C Treated With Pegylated Interferon
    Narkewicz, Michael R.
    Rosenthal, Philip
    Schwarz, Kathleen B.
    Drack, Arlene
    Margolis, Todd
    Repka, Michael X.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2010, 51 (02): : 183 - 186
  • [34] Treatment of chronic hepatitis C in HIV infected patients (pts) with pegylated interferon alpha 2b (PEG-IFN) plus ribavirin (RBV) versus pegylated interferon alpha 2b
    Cargnel, A
    Angeli, E
    Mainini, A
    Casella, A
    Gubertini, G
    Giorgi, R
    Orlando, G
    Duca, PG
    JOURNAL OF HEPATOLOGY, 2003, 38 : 132 - 132
  • [35] A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of Chronic Hepatitis C
    Sinha, S
    Gulur, P
    Patel, V
    Hage-Nassar, G
    Tenner, S
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S77 - S78
  • [36] Ophthalmic findings in chronic hepatitis C (CHC) patients treated with pegylated-interferon (PIFN) and ribavirin (RBV)
    Mehta, N
    Murthy, UK
    Kaul, V
    Abruzzese, GP
    Vadrevu, V
    Sveen, JB
    Teitelbaum, C
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S133 - S133
  • [37] Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis CA Meta-Analysis
    Nicolas Flori
    Natalie Funakoshi
    Yohan Duny
    Jean-Christophe Valats
    Michael Bismuth
    Dimitri Christophorou
    Jean-Pierre Daurès
    Pierre Blanc
    Drugs, 2013, 73 : 263 - 277
  • [38] The early HCV RNA dynamics in patients with acute hepatitis C treated with pegylated interferon-α2b
    De Rosa, FG
    Bargiacchi, O
    Audagnotto, S
    Garazzino, S
    Cariti, G
    Veronese, L
    Raiteri, R
    Calleri, G
    Di Perri, G
    ANTIVIRAL THERAPY, 2006, 11 (02) : 165 - 171
  • [39] Viral and STAT kinetics in patients with chronic hepatitis C treated with pegylated interferon A-2B plus ribavirin
    Malizia, Giuseppe
    Giannuoli, Gandolfo
    Gallo, Elena
    Madonia, Salvatore
    Aragona, Emma
    Dino, Ornello
    Pietrosi, Giodo
    Rizzo, Aroldo
    Patti, Salvatore
    Vitale, Maria Grazia
    Mondello, Patrizia
    Tine, Fabio
    HEPATOLOGY, 2007, 46 (04) : 355A - 355A
  • [40] Investigation of hyperuricemia during pegylated-interferon-α2b plus ribavirin combination therapy in patients with chronic hepatitis C
    Yamashita, Naoki
    Enjoji, Munechika
    Kotoh, Kazuhiro
    Kato, Masaki
    Ueda, Akihiro
    Horikawa, Yuki
    Tajiri, Hirotaka
    Higuchi, Nobito
    Kinukawa, Naoko
    Nakamuta, Makoto
    Takayanagi, Ryoichi
    JOURNAL OF DIGESTIVE DISEASES, 2008, 9 (01) : 27 - 31